UCB (OTCMKTS:UCBJF) Sees Unusually-High Trading Volume – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares saw strong trading volume on Thursday . 5,872 shares traded hands during trading, an increase of 551% from the previous session’s volume of 902 shares.The stock last traded at $292.69 and had previously closed at $304.6375.

Analyst Upgrades and Downgrades

UCBJF has been the topic of a number of research analyst reports. Wolfe Research assumed coverage on shares of UCB in a research report on Monday, February 23rd. They issued an “outperform” rating on the stock. Barclays reiterated an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a research note on Monday, December 8th. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, UCB presently has a consensus rating of “Buy”.

UCB Stock Performance

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $312.11 and its two-hundred day simple moving average is $287.32.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.